Stockreport

Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF 2026 and planned Phase 3 and Phase 2b trial initiations for nalbuphine ER in idiopathic pulmonary fibrosis and refractory chronic cough patients, respectively. This pr [Read more]